Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin added to insulin with or without metformin in Chinese patients with T2DM
NCT02104804Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of saxagliptin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started May 2014; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02104804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02104804.